52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
European Medicines Agency Accepts Biogen’S Aducanumab Marketing Authorization Application For Alzheimer's Disease
Biogen Inc Says Third Quarter Revenue $3,376 Million
Biogen Announces New $5.0 Billion Share Repurchase Authorization
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
Biotechnology & Drugs
225 Binney St
Stelios B. Papadopoulos
Independent Chairman of the Board
Chief Executive Officer, Director
Michael R. McDonnell
Chief Financial Officer, Executive Vice President
Chief Human Resource Officer, Executive Vice President
Susan H. Alexander
Executive Vice President, Chief Legal Officer and Secretary
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Healthcare and chemicals group Merck KGaA <MRCG.DE> lifted its guidance for full year earnings after the scramble to ready treatments and vaccines against the coronavirus bolstered demand for its supplies for biotech labs.
Biogen Inc's <BIIB.O> shares slumped about 30% on Monday as the drugmaker's chances of getting a regulatory approval for its experiment Alzheimer's treatment suffered a blow after a panel of experts to the U.S. Food and Drug Administration voted against the medicine.
A panel of outside advisers to the U.S. Food and Drug Administration on Friday voted that a potential Alzheimer’s treatment from Biogen Inc has not been proven to slow progression of the disease, a sharp rebuke to agency staff who earlier this week praised the drug.
A panel of outside advisers to the U.S. Food and Drug Administration on Friday voted that one of two large studies on Biogen Inc's experimental Alzheimer's disease drug cannot be viewed alone without regard for the other failed trial.
A meeting of outside advisers to the U.S. Food and Drug Administration convened on Friday to discuss whether to recommend approval of Biogen Inc's experimental Alzheimer's disease drug aducanumab.
Biogen Inc has shown "exceptionally persuasive" evidence that its experimental Alzheimer's disease drug is effective, U.S. Food and Drug Administration staff said on Wednesday, elevating its chances of a swift approval and sending company shares soaring.
U.S. health experts this week will decide whether to recommend approval for Biogen Inc's <BIIB.O> Alzheimer's drug, which could become the first new treatment for the mind-wasting disease in decades even as serious questions persist over whether data show if it works.
Biogen Inc and Eisai Co Ltd said on Friday the European health regulator has accepted for review the marketing application for their closely watched experimental Alzheimer's treatment aducanumab.
Biogen Inc and partner Eisai Co Ltd said on Friday the European health regulator has accepted for review the marketing application for its closely-watched experimental Alzheimer's treatment aducanumab.
Biogen Inc said on Wednesday it was diverting part of its budget and resources for blockbuster multiple sclerosis drug Tecfidera towards a potential launch of its Alzheimer's disease drug, aducanumab.
* BIOGEN INC CEO SAYS UPCOMING FDA PANEL MEETING FOR ADUCANUMAB IS CO'S HIGHEST PRIORITY: CONF. CALL
U.S. drugmaker Biogen Inc and gene-editing startup Scribe Therapeutics Inc will jointly develop therapies for treating underlying genetic causes of amyotrophic lateral sclerosis (ALS), a fatal neurological disorder better known as Lou Gehrig's disease.
The U.S. Food and Drug Administration will conduct an expedited review of an experimental Alzheimer's drug from Biogen Inc and Japan's Eisai Co Ltd, the companies said on Friday, the first application in 17 years to be reviewed by the agency for a treatment of the mind-robbing...
Biogen Inc and Japan's Eisai Co Ltd said on Friday the U.S. Food and Drug Administration has accepted their marketing application for experimental Alzheimer's disease treatment aducanumab.
Biogen Inc <BIIB.O> raised its 2020 earnings forecast on Wednesday after better-than-expected sales of its multiple sclerosis treatment Tecfidera helped the drugmaker beat second-quarter profit estimates.
Drugmaker Biogen Inc beat analysts' estimates for quarterly profit on Wednesday on better-than-expected sales of its multiple sclerosis treatment Tecfidera, and boosted its 2020 profit outlook.
Biogen Inc reported a 3.2% rise in second-quarter profit on Wednesday, getting a lift from demand for its top-selling multiple sclerosis drug Tecfidera.
Biogen Inc on Tuesday named IQVIA Holding Inc's Michael McDonnell as chief financial officer, effective Aug. 15.
One of medicine's costliest treatment areas could become even more pricey as Biogen <BIIB.O> seeks to layer its $750,000 spinal muscular atrophy drug on top of $2.1 million (1.66 million pounds)-per-patient Novartis <NOVN.S> gene therapy Zolgensma.
Novartis <NOVN.S> Chief Executive Vas Narasimhan said spinal muscular atrophy patients who got the Swiss drugmaker's Zolgensma maintained improvements, a response to Biogen's <BIIB.O> plan to test its drug Spinraza after Zolgensma treatment.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.